We are constantly conducting clinical trials for eye care advancement. We are committed to continued research. We collect data and insights, then make recommendations based on these to the medical community.
We collaborate with some of the world’s best research centers, pharmaceutical firms, lens and equipment manufacturers, to advance eye care and produce next-generation eye care technology.
Our research on ophthalmology has generated over 30 clinical trials for leading industry partners, published over 60 scientific articles and delivered hundreds of presentations in scientific fora.
We have ongoing clinical trials, so if you’re interested to participate as a patient, just get in touch with us. These clinical trials are designed for our mutual benefit.
Clinical trials are research studies that explore whether a medical strategy, treatment, or device is safe and effective for humans. These studies also may show which medical approaches work best for certain illnesses or groups of people.
INSTITUTIONAL REVIEW BOARD – An independent body constituted of medical, scientific, and non-scientific members, whose responsibility is to ensure the protection of the rights, safety and well-being of human subjects in a trial by, among other things, reviewing, approving, and providing continuing review of trial protocol and amendments and of the methods and material to be used in obtaining and documenting informed consent of the trial subjects. ICH-GCP E6 (R1)Other Names of Institutional Review Boards:
The PELI-IRB is responsible for the ethical review of research involving human participants conducted under or in collaboration with the Peregrine Eye and Laser Institute.
It ensures that all research:
Since its inception, research has been a key ingredient in Peregrine Eye and Laser Institute’s (PELI) aspirations to provide excellent, modern, evidence-based quality care to its patients. Only through responsive ethical researches can up-to-date interventions and better patient options become readily available to improve health outcomes. Without the benefit of researches, Filipino patients would suffer the indignity of having to settle for prehistoric modes of treatment and stagnant choices. This is one of the prime motivations in the establishment of the PELI Institutional Review Board in CY 2012. The IRB has provided ethical guidance and patient safeguards in the pursuit of responsive clinical researches that benefit not only PELI patients but all Filipinos nationwide. It is also pioneering in that it is one of a few institutional review boards outside the confines of a hospital setting. PELI researches have contributed positively to the entry of innovative solutions in the country as well as improved patient outcomes for many Filipinos.
With the growing complexities of numerous diseases, the evolution of basic sciences in the understanding of these disorders, and the endless possibilities of interactions between and among disease entities, the approach of PELI must equally evolve to be more holistic in order to serve the needs of its patients fully. It must also be facilitative in assessing innovative new medicines, medical supplies, and therapeutic interventions. These consequently place a burden on the institution to do more researches to remain true to its goal for its patients.
The value of being patient centric is at the heart of PELI. All researches should be designed to improve the quality of lives of patients, so too should these researches assure the safety and welfare of research participants, especially those trying out innovative treatment options. Patient rights must be continuously upheld in line with local and international ethical and regulatory standards.
In this regard, the IRB must also be responsive and must evolve to safeguard the interests of patients and research participants, among others. It should remain independent, well represented, and compliant with existing non-discriminatory public policies and regulatory standards. To this end, the IRB shall be improved and developed to be able to continuously achieve its duty to facilitate innovative researches without compromising ethics, patient safety, welfare and rights. PELI-IRB SOP Chap 1-Introduction
Guidelines and Standard Operating Procedures (SOPs)
The PELI-IRB provides access to its current ethical guidelines and procedures to ensure transparency and proper guidance for researchers.
Available Documents
References
Local Guidelines
2022 National Ethical Guidelines
2024 PHREB Policies and Requirements for Accreditation
20160825-IRR-RA-10173-data-privacy
DOH AO2020-0010 Regulations on the Conduct of Clinical Trials for Investigational Products
DOH AO671989 Revised Rules and Regulations on Registration of Pharmaceutical Products
DOH DO2017-0265 Streamling Ethics Review (1)
DOH DO2017-0265 Streamling Ethics Review
FC2020-001-A Medical Devices Classifications
PELI-IRB Standard Operating Procedures
Review Process and Requirements
PELI- IRB Forms
Pre- Approval Forms
Post-Approval Forms
Source of Funding
Approved Research Studies
PELI IRB MEMBERS
Your rights and welfare are our priority.
You may contact the PELI-IRB if you:
The PELI-IRB provides a clear and accessible mechanism for participants, researchers, and stakeholders to raise concerns regarding participants’ rights and the ethics review process.
Email: peli.irb@peregrineeye.com
Phone: (02) 8900-0115 loc. 113
Office Address: 5F PELI-IRB Rm., 347 Sen. Gil J. Puyat Ave, Makati, 1209 Metro Manila Philippines
Office Hours: Monday to Friday (9:00 am to 5:00 pm)